Other News To Note
Wednesday, June 29, 2011
Theratechnologies Inc., of Montreal, reported that the marketing authorization application (MAA) for tesamorelin submitted by its partner, Ferrer Internacional SA, of Barcelona, Spain, was accepted for review by the European Medicines Agency. The MAA is based on positive results from two Phase III trials that enrolled more than 800 patients and follows tesamorelin's marketing approval by the FDA in November 2010 under the trade name Egrifta. Tesamorelin is designed to treat HIV-associated lipodystrophy, a metabolic complication that affects patients taking antiretroviral therapies long term.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.